ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the ...
Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency. The posters will be made available on the Amicus website following their respective ...
- Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1 and the first treated patients in dose Cohort 2 - Additional presentations include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback